MID-VOLUME · SEX-BALANCED
alirocumab Side Effects
alirocumab (also sold as Praluent) sits MID-VOLUME #212 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 59% of sex-coded reports are female (12,559 F / 8,648 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 24,428
- FAERS reports
FDA Adverse Event Reporting System extract for alirocumab. Stamp set WATCHLIST · DEATH-MARKED · HOSP-MID. How figures are compiled.
alirocumab reporting skew - 59% of sex-coded reports are female (12,559 F / 8,648 M). Volume band MID-VOLUME #212 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for alirocumab (Praluent) (24,428 reports). Signature SEX-BALANCED. Dominant age band on file: 65-74. Educational reference only.
Counts from the openFDA FAERS extract (2008–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
MYALGIA leads 1,655 of 24,428 reports
Who reports · age peak 65-74 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 65-74 (5,189 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 492 reports (2.0% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 285 |
| MYOCARDIAL INFARCTION | 30 |
| CARDIAC ARREST | 23 |
| CARDIAC FAILURE | 15 |
| DYSPNOEA | 14 |
| CARDIAC FAILURE CONGESTIVE | 11 |
| CEREBROVASCULAR ACCIDENT | 11 |
| COUGH | 11 |
| HOSPITALISATION | 11 |
| PNEUMONIA | 11 |
| ASTHENIA | 10 |
| NEOPLASM MALIGNANT | 10 |
| CARDIAC DISORDER | 9 |
| CARDIOGENIC SHOCK | 9 |
| COMPLETED SUICIDE | 9 |
| FALL | 9 |
| RESPIRATORY ARREST | 9 |
| ACUTE MYOCARDIAL INFARCTION | 8 |
| COVID-19 | 8 |
| FATIGUE | 8 |
Reactions in Hospitalization Reports
Hospitalization mid-share (2,529, 10.4%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| MYOCARDIAL INFARCTION | 236 |
| HOSPITALISATION | 175 |
| CEREBROVASCULAR ACCIDENT | 169 |
| DYSPNOEA | 145 |
| CHEST PAIN | 131 |
| FALL | 120 |
| PNEUMONIA | 116 |
| NAUSEA | 108 |
| DIZZINESS | 105 |
| DIARRHOEA | 102 |
| MALAISE | 97 |
| FATIGUE | 94 |
| MYALGIA | 89 |
| PAIN | 87 |
| ASTHENIA | 79 |
| CARDIAC DISORDER | 75 |
| PAIN IN EXTREMITY | 72 |
| HEADACHE | 70 |
| VOMITING | 69 |
How to read alirocumab FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-MID)
FAERS holds 24,428 voluntary reports linked to alirocumab (Praluent), 2008-2025. Death is listed on 492 (2.0%). Hospitalization appears on 2,529 (10.4%). Top co-reported indication: Hyperlipidaemia.
Mid-volume extract - treat DEATH-MARKED · HOSP-MID as signal-detection rates next to 59% of sex-coded reports are female (12,559 F / 8,648 M).
Read with alirocumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 24,367 FAERS cases (Δ 61 lighter vs alirocumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 24,340 FAERS cases (Δ 88 lighter vs alirocumab); DEATH-HEAVY · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 24,667 FAERS cases (Δ 239 heavier vs alirocumab); DEATH-MARKED · HOSP-LIGHT · FEMALE-LED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 24,014 FAERS cases (Δ 414 lighter vs alirocumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 60.1 pp vs alirocumab's DEATH-MARKED): CASELOAD · HOSP-MID.
alirocumab stamps WATCHLIST · SEX-BALANCED; class peers and methodology beat restating the same FAERS caveats on every effects URL.